$4.36
Live
1.61%
Downside
Day's Volatility :5.71%
Upside
4.18%
7.11%
Downside
52 Weeks Volatility :69.29%
Upside
66.94%
Period | Caribou Biosciences | |
---|---|---|
3 Months | -18.87% | |
6 Months | -50.17% | |
1 Year | -48.74% | |
3 Years | -72.61% |
Market Capitalization | 293.3M |
Book Value | $4.54 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -1.87 |
Wall Street Target Price | 28.43 |
Profit Margin | 0.0% |
Operating Margin TTM | -794.21% |
Return On Assets TTM | -18.38% |
Return On Equity TTM | -33.34% |
Revenue TTM | 14.7M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | 31.5% |
Gross Profit TTM | -68.4M |
EBITDA | -114.8M |
Diluted Eps TTM | -1.87 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.96 |
EPS Estimate Next Year | -2.36 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.5 |
What analysts predicted
Upside of 552.06%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 5.8M | - |
Net Income | -23.4M | - |
Net Profit Margin | -404.82% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 12.4M | ↑ 113.56% |
Net Income | -34.3M | ↑ 46.42% |
Net Profit Margin | -277.55% | ↑ 127.27% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 9.6M | ↓ 22.35% |
Net Income | -66.9M | ↑ 95.07% |
Net Profit Margin | -697.26% | ↓ 419.71% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 13.9M | ↑ 44.31% |
Net Income | -99.4M | ↑ 48.56% |
Net Profit Margin | -717.79% | ↓ 20.53% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | -2.9M | ↓ 172.77% |
Net Income | -18.5M | ↓ 11.9% |
Net Profit Margin | 638.53% | ↑ 1165.91% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↓ 192.05% |
Net Income | -19.1M | ↑ 3.3% |
Net Profit Margin | -716.52% | ↓ 1355.05% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 4.2M | ↑ 57.36% |
Net Income | -26.7M | ↑ 39.86% |
Net Profit Margin | -636.86% | ↑ 79.66% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.3M | ↓ 21.21% |
Net Income | -26.6M | ↓ 0.19% |
Net Profit Margin | -806.75% | ↓ 169.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.7M | ↑ 11.78% |
Net Income | -27.0M | ↑ 1.28% |
Net Profit Margin | -731.01% | ↑ 75.74% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.5M | ↓ 5.15% |
Net Income | -28.0M | ↑ 3.91% |
Net Profit Margin | -800.8% | ↓ 69.79% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 61.9M | - |
Total Liabilities | 13.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 36.0M | ↓ 41.8% |
Total Liabilities | 18.2M | ↑ 38.13% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 442.4K | ↓ 98.77% |
Total Liabilities | 54.5K | ↓ 99.7% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 373.8K | ↓ 15.51% |
Total Liabilities | 72.9K | ↑ 33.67% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 442.4M | ↓ 4.24% |
Total Liabilities | 54.5M | ↓ 5.26% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 446.0M | ↑ 0.82% |
Total Liabilities | 74.2M | ↑ 36.07% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 421.4M | ↓ 5.52% |
Total Liabilities | 73.5M | ↓ 0.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 398.8M | ↓ 5.35% |
Total Liabilities | 74.7M | ↑ 1.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 373.8M | ↓ 6.28% |
Total Liabilities | 72.9M | ↓ 2.43% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 347.5M | ↓ 7.04% |
Total Liabilities | 69.2M | ↓ 5.08% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.0M | - |
Investing Cash Flow | 27.2M | - |
Financing Cash Flow | 172.0K | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.2M | ↑ 3.78% |
Investing Cash Flow | 6.4M | ↓ 76.63% |
Financing Cash Flow | 1.7M | ↑ 908.72% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -32.5M | ↓ 2.1% |
Investing Cash Flow | -176.4M | ↓ 2872.23% |
Financing Cash Flow | 433.4M | ↑ 24881.5% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -91.0M | ↑ 179.73% |
Investing Cash Flow | -93.2M | ↓ 47.14% |
Financing Cash Flow | 2.1M | ↓ 99.51% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.4M | ↑ 42.91% |
Investing Cash Flow | -174.0M | ↑ 8913.52% |
Financing Cash Flow | 460.0K | ↓ 99.86% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.7M | ↑ 1.33% |
Investing Cash Flow | -72.1M | ↓ 58.55% |
Financing Cash Flow | 990.0K | ↑ 115.22% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.9M | ↑ 0.92% |
Investing Cash Flow | -14.0M | ↓ 80.62% |
Financing Cash Flow | 362.0K | ↓ 63.43% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -65.9M | ↑ 201.39% |
Investing Cash Flow | -8.3M | ↓ 40.32% |
Financing Cash Flow | 2.0M | ↑ 454.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 18.5M | ↓ 128.07% |
Investing Cash Flow | 1.2M | ↓ 114.03% |
Financing Cash Flow | -1.2M | ↓ 161.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.9M | ↓ 251.01% |
Investing Cash Flow | 20.7M | ↑ 1669.49% |
Financing Cash Flow | 1.6M | ↓ 234.04% |
Sell
Neutral
Buy
Caribou Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Caribou Biosciences | 1.59% | -50.17% | -48.74% | -72.61% | -72.61% |
![]() Moderna, Inc. | -6.6% | -29.55% | -6.79% | 114.56% | 571.72% |
![]() Regeneron Pharmaceuticals, Inc. | -0.63% | 0.01% | 30.35% | 23.26% | 140.46% |
![]() Novo Nordisk A/s | -5.39% | 23.69% | 41.34% | 146.71% | 255.68% |
![]() Seagen, Inc. | -2.64% | 57.03% | 37.37% | 30.74% | 191.76% |
![]() Vertex Pharmaceuticals Incorporated | -3.55% | 6.52% | 28.06% | 22.79% | 123.76% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Caribou Biosciences | NA | NA | NA | -1.96 | -0.33 | -0.18 | 0.0 | 4.54 |
![]() Moderna, Inc. | 10.88 | 10.88 | 0.0 | -1.74 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 20.15 | 20.15 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Novo Nordisk A/s | 41.07 | 41.07 | 2.03 | 4.99 | 0.84 | 0.23 | 0.01 | 4.44 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.89 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 25.51 | 25.51 | 0.41 | 14.57 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Caribou Biosciences | Buy | $293.3M | -72.61% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $47.9B | 571.72% | 10.88 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $81.0B | 140.46% | 20.15 | 33.81% |
![]() Novo Nordisk A/s | Buy | $356.5B | 255.68% | 41.07 | 32.47% |
![]() Seagen, Inc. | Hold | $36.5B | 191.76% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $85.1B | 123.76% | 25.51 | 35.4% |
Partner Fund Management LP
BlackRock Inc
State Street Corporation
Avidity Partners Management LP
Rokos Capital Management LLP
Vanguard Group Inc
Caribou Biosciences’s price-to-earnings ratio stands at None
Read MoreOrganization | Caribou Biosciences |
Employees | 137 |
CEO | Dr. Rachel E. Haurwitz Ph.D. |
Industry | Services |